Abstract:There has been over half a century since the discovery of hepatitis B virus (HBV) to now, but approximately 300 million patients with chronic hepatitis B (CHB) still live in the world, resulting in about one million deaths every year. Although currently approved antivirals (e.g., nucleoside analogues) are effective at reducing HBV replication, they have almost no impact on the existing HBV covalently closed circular DNA (cccDNA) reservoir. HBV cccDNA is a critical obstacle to the complete elimination of the virus via antiviral therapy. The true cure of HBV infection requires the eradication of viral cccDNA from HBV-infected cells; thus, the development of new agents directly or indirectly targeting HBV cccDNA is urgently needed due to the limitations of current available drugs against HBV infection. In this regard, it is the major focus of current anti-HBV research worldwide via different mechanisms to either inactivate/inhibit (functional cure) or eliminate (complete cure) HBV cccDNA. Therefore, this review discussed and summarized recent advances and challenges in efforts to inactivate/silence or eliminate viral cccDNA using anti-HBV agents from different sources, such as small molecules (including epigenetic drugs) and polypeptides/proteins, and siRNA or gene-editing approaches targeting/attenuating HBV cccDNA via different mechanisms, as well as future directions that may be considered in efforts to truly cure chronic HBV infection. In conclusion, no breakthrough has been made yet in attenuating HBV cccDNA, although a number of candidates have advanced into the phase of clinical trials. Furthermore, the overwhelming majority of the candidates function to indirectly target HBV cccDNA. No outstanding candidate directly targets HBV cccDNA. Relatively speaking, CCC_R08 and nitazoxanide may be some of the most promising agents to clear HBV infection in small molecule compounds. Additionally, CRISPR-Cas9 systems can directly target HBV cccDNA for decay and demonstrate significant anti-HBV activity. Consequently, gene-editing approaches targeting HBV cccDNA may be one of the most promising means to achieve the core goal of anti-HBV therapeutic strategies. In short, more basic studies on HBV infection need to be carried out to overcome these challenges.

Overview of the Development of HBV Small Molecule Inhibitors

Current trends and advances in antiviral therapy for chronic hepatitis B

Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA.

Novel mechanistic insights – A brand new Era for anti-HBV drugs

Getting to HBV cure: The promising paths forward

Anti-Hbv Drugs: Progress, Unmet Needs, and New Hope

New advances in drug therapy of chronic hepatitis B infection

Therapeutic strategies for hepatitis B virus infection: towards a cure

Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B

Progress of Infection and Replication Systems of Hepatitis B Virus

HBV life cycle and novel drug targets

Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus

Developments in pharmacotherapeutic agents for hepatitis B - how close are we to a functional cure?

Perspectives in the Development of New Drugs Against Hepatitis B Virus

New anti-hepatitis B virus drugs under development and evaluation.

New Anti-Hepatitis B Virus Drugs under Development and Evaluation

Hepatitis B: Model Systems and Therapeutic Approaches

Advances in Research and Development of New Drugs for Antiviral Therapy for Chronic Hepatitis B

Emerging Antivirals for the Treatment of Hepatitis B

Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection

Potential Drug Targets Against Hepatitis B Virus Based on Both Virus and Host Factors.